Drugs / Momordica charantia
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02397447 | Mar 2013 → Nov 2015 | type 2 diabetes mellitus | University of Guadalajara | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00823953 Comparator | Nov 2008 → Feb 2009 | type 2 diabetes mellitus | Services Hospital, Lahore | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Momordica charantia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02397447 ↗ |
| Route | Oral | “Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days” NCT02397447 ↗ |